Pathway,q_value,p_value,cliffs_delta,delta_median(label1 - label0),median_label0,median_label1,n_label0,n_label1,effect_size_magnitude,direction
NOTCH1 Intracellular Domain Regulates Transcription,4.2751007120983355e-07,3.125399998400872e-08,1.0,0.14657534024280588,-0.14648851090700304,8.68293358028475e-05,21,21,large,higher_in_label1(disease)
Bacterial Infection Pathways,4.2751007120983355e-07,3.125399998400872e-08,1.0,0.17953741137930546,-0.1786977604665804,0.00083965091272505,21,21,large,higher_in_label1(disease)
Signaling by NOTCH2,4.2751007120983355e-07,3.125399998400872e-08,1.0,0.253123447126062,-0.2527326578341902,0.0003907892918718,21,21,large,higher_in_label1(disease)
Signaling by MET,4.2751007120983355e-07,3.125399998400872e-08,1.0,0.0318358540977265,-0.0034684585863925,0.028367395511334,21,21,large,higher_in_label1(disease)
Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters,4.2751007120983355e-07,3.125399998400872e-08,1.0,0.03192087275075875,-0.0028171423104269497,0.0291037304403318,21,21,large,higher_in_label1(disease)
Diseases of DNA repair,4.2751007120983355e-07,3.125399998400872e-08,1.0,0.0241986833660849,-0.0031072029117265,0.0210914804543584,21,21,large,higher_in_label1(disease)
Defective homologous recombination repair (HRR) due to BRCA1 loss of function,4.2751007120983355e-07,3.125399998400872e-08,1.0,0.03494878651848796,-0.0349657458684503,-1.695934996233442e-05,21,21,large,higher_in_label1(disease)
Impaired BRCA2 binding to RAD51,4.2751007120983355e-07,3.125399998400872e-08,1.0,0.0996111645377107,-0.0033044832796687,0.096306681258042,21,21,large,higher_in_label1(disease)
Impaired BRCA2 binding to PALB2,4.2751007120983355e-07,3.125399998400872e-08,1.0,0.019119177951528697,-0.0025823619661002,0.0165368159854285,21,21,large,higher_in_label1(disease)
TNFR1-induced NF-kappa-B signaling pathway,4.2751007120983355e-07,3.125399998400872e-08,1.0,0.0514764872417597,-0.0029906745846989,0.0484858126570608,21,21,large,higher_in_label1(disease)
Signaling by Retinoic Acid,4.2751007120983355e-07,3.125399998400872e-08,1.0,0.45194246937511146,-0.4511468466884152,0.0007956226866962499,21,21,large,higher_in_label1(disease)
RA biosynthesis pathway,4.2751007120983355e-07,3.125399998400872e-08,1.0,0.2582871829005741,-0.2579083019452339,0.0003788809553402,21,21,large,higher_in_label1(disease)
NOTCH2 Activation and Transmission of Signal to the Nucleus,4.2751007120983355e-07,3.125399998400872e-08,1.0,0.0791698613306347,-0.006816729315378399,0.0723531320152563,21,21,large,higher_in_label1(disease)
Opioid Signalling,4.2751007120983355e-07,3.125399998400872e-08,1.0,0.2963745821867241,-0.2957325189131699,0.0006420632735542,21,21,large,higher_in_label1(disease)
Signaling by NTRK2 (TRKB),4.2751007120983355e-07,3.125399998400872e-08,1.0,0.1038043687924143,-0.1034279665227065,0.0003764022697078,21,21,large,higher_in_label1(disease)
RHOBTB GTPase Cycle,4.2751007120983355e-07,3.125399998400872e-08,1.0,0.20366766001694592,-0.2032075894814167,0.0004600705355292,21,21,large,higher_in_label1(disease)
Signaling by ALK in cancer,4.2751007120983355e-07,3.125399998400872e-08,1.0,0.4163579144957113,-0.4149598321236929,0.0013980823720184,21,21,large,higher_in_label1(disease)
Signaling by ALK fusions and activated point mutants,4.2751007120983355e-07,3.125399998400872e-08,1.0,0.16845071328299335,-0.16833253151177946,0.0001181817712139,21,21,large,higher_in_label1(disease)
RHOQ GTPase cycle,4.2751007120983355e-07,3.125399998400872e-08,1.0,0.8251944788914362,-0.8230990519709525,0.0020954269204837,21,21,large,higher_in_label1(disease)
Aberrant regulation of mitotic exit in cancer due to RB1 defects,4.2751007120983355e-07,3.125399998400872e-08,1.0,0.0676700618112938,-0.0025179225545042,0.0651521392567896,21,21,large,higher_in_label1(disease)
SARS-CoV-1-host interactions,4.2751007120983355e-07,3.125399998400872e-08,1.0,0.4219734300387334,-0.4213416052844341,0.0006318247542993,21,21,large,higher_in_label1(disease)
HCMV Late Events,4.2751007120983355e-07,3.125399998400872e-08,1.0,0.21016086015244959,-0.20914298089405164,0.00101787925839795,21,21,large,higher_in_label1(disease)
Late SARS-CoV-2 Infection Events,4.2751007120983355e-07,3.125399998400872e-08,1.0,0.6397171613506614,-0.6375514013127419,0.0021657600379194498,21,21,large,higher_in_label1(disease)
Viral Messenger RNA Synthesis,4.2751007120983355e-07,3.125399998400872e-08,1.0,0.0439722265517941,-0.0030238309748632,0.0409483955769309,21,21,large,higher_in_label1(disease)
Signaling by AXIN mutants,4.2751007120983355e-07,3.125399998400872e-08,1.0,0.0304844296975121,-0.00098172059863345,0.02950270909887865,21,21,large,higher_in_label1(disease)
APC truncation mutants have impaired AXIN binding,4.2751007120983355e-07,3.125399998400872e-08,1.0,0.06488438490699922,-0.06480721194301665,7.717296398255943e-05,21,21,large,higher_in_label1(disease)
Defective pyroptosis,4.2751007120983355e-07,3.125399998400872e-08,1.0,0.3269467839418011,-0.3264591856975117,0.0004875982442894,21,21,large,higher_in_label1(disease)
Competing endogenous RNAs (ceRNAs) regulate PTEN translation,4.2751007120983355e-07,3.125399998400872e-08,1.0,0.0082176416505097,-0.0015225093152196,0.0066951323352901,21,21,large,higher_in_label1(disease)
Cell recruitment (pro-inflammatory response),4.455876780721136e-07,3.606584339487081e-08,0.9954648526077097,0.0201630816053812,-0.0018952155106725,0.0182678660947087,21,21,large,higher_in_label1(disease)
Glucagon-type ligand receptors,4.455876780721136e-07,3.606584339487081e-08,0.9954648526077097,0.0487157143238863,-0.0031399798707489,0.0455757344531374,21,21,large,higher_in_label1(disease)
Maturation of hRSV A proteins,4.455876780721136e-07,3.606584339487081e-08,0.9954648526077097,0.03314838838329859,-0.0331335607074955,1.4827675803087091e-05,21,21,large,higher_in_label1(disease)
Signaling by EGFRvIII in Cancer,4.978152337560079e-07,4.1592917702851843e-08,0.9909297052154196,0.0077855285333408505,-0.0007537434643612,0.007031785068979651,21,21,large,higher_in_label1(disease)
Constitutive Signaling by NOTCH1 PEST Domain Mutants,8.4864624466203e-07,7.3120955806389e-08,0.9727891156462585,0.24217478126230732,-0.2415751403873868,0.0005996408749205,21,21,large,higher_in_label1(disease)
Interactions of Vpr with host cellular proteins,1.1481622226615268e-06,1.1091906589680546e-07,0.9591836734693877,0.0415449324589975,-0.000882199939785,0.0406627325192125,21,21,large,higher_in_label1(disease)
Response of Mtb to phagocytosis,1.1481622226615268e-06,1.1091906589680546e-07,0.9591836734693877,0.0359661015032834,-0.0009664825325318,0.0349996189707516,21,21,large,higher_in_label1(disease)
Insulin receptor signalling cascade,1.1481622226615268e-06,1.1091906589680546e-07,0.9591836734693877,0.14822416632027538,-0.1479767358555744,0.000247430464701,21,21,large,higher_in_label1(disease)
Signaling by Erythropoietin,1.1481622226615268e-06,1.1091906589680546e-07,0.9591836734693877,0.02196783380312,-0.0020249266988904497,0.01994290710422955,21,21,large,higher_in_label1(disease)
Degradation of GLI1 by the proteasome,1.4336716246518072e-06,1.4598745002981848e-07,-0.9501133786848073,-0.0527237279900608,0.0526207013918814,-0.0001030265981794,21,21,large,higher_in_label0(control)
RHOJ GTPase cycle,1.4336716246518072e-06,1.4598745002981848e-07,0.9501133786848073,0.06601703767790056,-0.0033891245860906,0.06262791309180996,21,21,large,higher_in_label1(disease)
RND1 GTPase cycle,1.602171817035061e-06,1.6732864929870087e-07,0.945578231292517,0.30135298348256323,-0.3007012302062181,0.00065175327634515,21,21,large,higher_in_label1(disease)
ERK/MAPK targets,1.790496635864761e-06,1.9167196363043132e-07,-0.9410430839002267,-0.0169742339705704,0.0003170160206482,-0.0166572179499222,21,21,large,higher_in_label0(control)
Downstream signaling of activated FGFR4,2.0009209627114804e-06,2.1942214212501873e-07,0.9365079365079365,0.0327301610280248,-0.0325775567719156,0.0001526042561092,21,21,large,higher_in_label1(disease)
Parasite infection,2.2359715198926478e-06,2.5103596698533647e-07,0.9319727891156462,0.10055804518001604,-0.0033707345625873,0.09718731061742875,21,21,large,higher_in_label1(disease)
Signaling by FGFR2 in disease,2.8549219625979653e-06,3.279805910034216e-07,0.9229024943310657,0.09397407933464953,-0.0940552081998249,-8.112886517535802e-05,21,21,large,higher_in_label1(disease)
Evasion by RSV of host interferon responses,3.1878012858044874e-06,3.7454584297963954e-07,0.9183673469387754,0.01618107199201175,-0.0017680281005652,0.014413043891446549,21,21,large,higher_in_label1(disease)
Budding and maturation of HIV virion,3.5590712504738235e-06,4.274602546260989e-07,0.9138321995464853,0.019382160197581648,-0.00096999696342235,0.0184121632341593,21,21,large,higher_in_label1(disease)
Hh mutants are degraded by ERAD,3.973026018350241e-06,4.875514957244422e-07,-0.909297052154195,-0.02366412848420609,0.0236039552866293,-6.0173197576791755e-05,21,21,large,higher_in_label0(control)
Regulation of RAS by GAPs,4.093311012928836e-06,5.557497980999986e-07,-0.9047619047619048,-0.03714278812881775,-0.0001587687662387,-0.03730155689505645,21,21,large,higher_in_label0(control)
Host Interactions of HIV factors,4.093311012928836e-06,5.557497980999986e-07,0.9047619047619047,0.14326513677316519,-0.1427271907491099,0.0005379460240553,21,21,large,higher_in_label1(disease)
Hh mutants abrogate ligand secretion,4.093311012928836e-06,5.557497980999986e-07,0.9047619047619047,0.0108197673779288,-0.0025899110023543,0.0082298563755745,21,21,large,higher_in_label1(disease)
Signaling by RAF1 mutants,4.093311012928836e-06,5.557497980999986e-07,0.9047619047619047,0.019125171416410302,-0.0020423546126141,0.0170828168037962,21,21,large,higher_in_label1(disease)
CTNNB1 S37 mutants aren't phosphorylated,4.093311012928836e-06,5.557497980999986e-07,0.9047619047619047,0.024726304103525748,-0.00188236867890265,0.0228439354246231,21,21,large,higher_in_label1(disease)
Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects,4.575042998298325e-06,6.330999449342329e-07,0.9002267573696145,0.12802324786408112,-0.1282404169541893,-0.0002171690901082,21,21,large,higher_in_label1(disease)
RHOD GTPase cycle,5.608822202285907e-06,8.200888859739185e-07,0.8911564625850341,0.0343048672338176,-0.0002314643405994,0.0340734028932182,21,21,large,higher_in_label1(disease)
Translation of Structural Proteins,5.608822202285907e-06,8.200888859739185e-07,0.8911564625850341,0.0398645133926121,-0.0020241397750239,0.0378403736175882,21,21,large,higher_in_label1(disease)
CTNNB1 T41 mutants aren't phosphorylated,5.608822202285907e-06,8.200888859739185e-07,0.8911564625850341,0.00959805977966945,-0.0014380142671801999,0.00816004551248925,21,21,large,higher_in_label1(disease)
Neurotoxicity of clostridium toxins,6.157827913029706e-06,9.325170207721226e-07,0.8866213151927438,0.0301805900440467,-0.0023242702297078,0.0278563198143389,21,21,large,higher_in_label1(disease)
Induction of Cell-Cell Fusion,6.157827913029706e-06,9.325170207721226e-07,0.8866213151927438,0.0352424909536279,-0.0350343608769177,0.0002081300767102,21,21,large,higher_in_label1(disease)
Asymmetric localization of PCP proteins,1.1402525083018454e-05,1.7565247516921379e-06,0.8639455782312926,0.08201783910284276,-0.0029963949887078503,0.0790214441141349,21,21,large,higher_in_label1(disease)
PI3K/AKT Signaling in Cancer,1.2702977344188884e-05,1.990022560447345e-06,0.8594104308390023,0.054167251754706096,-0.00070355938499,0.0534636923697161,21,21,large,higher_in_label1(disease)
RHOU GTPase cycle,1.4147040580290246e-05,2.2531840088712923e-06,0.8548752834467119,0.0243544624772409,-0.0008593215545257,0.0234951409227152,21,21,large,higher_in_label1(disease)
Signaling by SCF-KIT,1.5749886348320736e-05,2.5495899571694142e-06,-0.8503401360544218,-0.023780867384677898,0.0236542221879862,-0.0001266451966917,21,21,large,higher_in_label0(control)
Estrogen-dependent nuclear events downstream of ESR-membrane signaling,1.6988871886198883e-05,2.8832289101904107e-06,-0.8458049886621315,-0.02945667066285555,0.028941210011412748,-0.0005154606514428,21,21,large,higher_in_label0(control)
FRS-mediated FGFR2 signaling,1.6988871886198883e-05,2.8832289101904107e-06,0.8458049886621315,0.005521992675899451,-0.0009468881784637,0.0045751044974357506,21,21,large,higher_in_label1(disease)
SHC-mediated cascade:FGFR4,1.6988871886198883e-05,2.8832289101904107e-06,0.8458049886621315,0.0028117021877617997,-0.00101078994857915,0.0018009122391826498,21,21,large,higher_in_label1(disease)
FRS-mediated FGFR1 signaling,1.890940824565428e-05,3.2585403243164036e-06,0.8412698412698412,0.0093837638067551,-0.0003034295628808,0.0090803342438743,21,21,large,higher_in_label1(disease)
NOTCH3 Activation and Transmission of Signal to the Nucleus,2.103905970744517e-05,3.68046214203349e-06,0.8367346938775511,0.012766058453256951,-0.0018358288467253,0.010930229606531651,21,21,large,higher_in_label1(disease)
RHO GTPases Activate ROCKs,2.976065959996755e-05,5.2838769002553355e-06,-0.8231292517006803,-0.036043219879586134,0.035965720602252296,-7.749927733383724e-05,21,21,large,higher_in_label0(control)
Defective CFTR causes cystic fibrosis,3.211547793426962e-05,5.9535220191465886e-06,0.81859410430839,0.020537423458271,-0.0015013117266219,0.0190361117316491,21,21,large,higher_in_label1(disease)
RNA Pol II CTD phosphorylation and interaction with CE during HIV infection,3.211547793426962e-05,5.9535220191465886e-06,-0.81859410430839,-0.03281580746640363,0.032784189680238704,-3.161778616493094e-05,21,21,large,higher_in_label0(control)
G alpha (z) signalling events,3.211547793426962e-05,5.9535220191465886e-06,0.81859410430839,0.12812471530679911,-0.1281725671408097,-4.7851834010588957e-05,21,21,large,higher_in_label1(disease)
Signaling by AMER1 mutants,4.013193389179744e-05,7.544384439189074e-06,0.8095238095238095,0.0027048977536221503,-0.00055754661901465,0.0021473511346075,21,21,large,higher_in_label1(disease)
TNFR1-induced proapoptotic signaling,4.4517266392575785e-05,8.485014221039249e-06,0.8049886621315192,0.012197427202526792,-6.487028972884218e-05,0.012132556912797951,21,21,large,higher_in_label1(disease)
G alpha (s) signalling events,4.936105296807416e-05,9.537122505580907e-06,0.8004535147392291,0.12852360967712562,-0.1284418801204403,8.17295566853211e-05,21,21,large,higher_in_label1(disease)
Signaling by TGFBR3,5.398877216968768e-05,1.0713176722966746e-05,0.7959183673469388,0.0367701729185721,-0.00317617918657145,0.03359399373200065,21,21,large,higher_in_label1(disease)
IGF1R signaling cascade,5.398877216968768e-05,1.0713176722966746e-05,0.7959183673469388,0.16778049409808435,-0.16734080639876664,0.0004396876993177,21,21,large,higher_in_label1(disease)
DAG and IP3 signaling,5.8307857017361784e-05,1.2026947008803083e-05,-0.7913832199546486,-0.07588105295742749,0.0749411188507434,-0.0009399341066841,21,21,large,higher_in_label0(control)
Constitutive Signaling by AKT1 E17K in Cancer,5.8307857017361784e-05,1.2026947008803083e-05,0.7913832199546484,0.026131392485146752,-0.0024325957061299003,0.023698796779016852,21,21,large,higher_in_label1(disease)
FGFR4 ligand binding and activation,5.8307857017361784e-05,1.2026947008803083e-05,0.7913832199546484,0.00993294172353445,-0.0001879637921281,0.00974497793140635,21,21,large,higher_in_label1(disease)
RSV-host interactions,6.380322078309576e-05,1.3493631549427563e-05,0.7868480725623583,0.017531656504598703,-0.001130157627252,0.016401498877346703,21,21,large,higher_in_label1(disease)
RHOBTB2 GTPase cycle,6.380322078309576e-05,1.3493631549427563e-05,0.7868480725623583,0.0201920054423264,-0.0027719630712033996,0.017420042371123,21,21,large,higher_in_label1(disease)
Regulation of PTEN gene transcription,6.898556232488679e-05,1.512999278143731e-05,0.782312925170068,0.0490964157718391,-0.0016585466855018,0.0474378690863373,21,21,large,higher_in_label1(disease)
DARPP-32 events,6.898556232488679e-05,1.512999278143731e-05,0.782312925170068,0.01358522925847735,-0.0005380376637978,0.01304719159467955,21,21,large,higher_in_label1(disease)
Diseases of mitotic cell cycle,6.898556232488679e-05,1.512999278143731e-05,-0.782312925170068,-0.0551690504575822,0.0548186181262583,-0.0003504323313239,21,21,large,higher_in_label0(control)
Oncogenic MAPK signaling,7.215083903800167e-05,1.6954505256971672e-05,-0.7777777777777778,-0.08078057602785492,0.0807420248550133,-3.855117284162061e-05,21,21,large,higher_in_label0(control)
"Cell death signalling via NRAGE, NRIF and NADE",7.215083903800167e-05,1.6954505256971672e-05,0.7777777777777777,0.036452673181955754,-0.0021216383397206,0.03433103484223515,21,21,large,higher_in_label1(disease)
Pausing and recovery of HIV elongation,7.215083903800167e-05,1.6954505256971672e-05,0.7777777777777777,0.15846852581728957,-0.1580858669619384,0.00038265885535115,21,21,large,higher_in_label1(disease)
Insulin receptor recycling,7.215083903800167e-05,1.6954505256971672e-05,0.7777777777777777,0.07890830726174225,-0.0021664866796218,0.07674182058212045,21,21,large,higher_in_label1(disease)
RND3 GTPase cycle,7.215083903800167e-05,1.6954505256971672e-05,0.7777777777777777,0.0176031193362636,-0.0010476788164527,0.0165554405198109,21,21,large,higher_in_label1(disease)
Formation of the beta-catenin:TCF transactivating complex,7.215083903800167e-05,1.6954505256971672e-05,0.7777777777777777,0.0400942235098852,-0.00386970577243975,0.03622451773744545,21,21,large,higher_in_label1(disease)
RHOBTB3 ATPase cycle,8.751928263613298e-05,2.125141849911323e-05,0.7687074829931972,0.011221039631818499,-0.0006020991591541,0.0106189404726644,21,21,large,higher_in_label1(disease)
Assembly Of The HIV Virion,8.751928263613298e-05,2.125141849911323e-05,-0.7687074829931972,-0.0031917448967398,0.0001317052373913,-0.0030600396593485,21,21,large,higher_in_label0(control)
PI-3K cascade:FGFR1,8.751928263613298e-05,2.125141849911323e-05,0.7687074829931972,0.017470526583614112,-0.0174804015613542,-9.874977740085708e-06,21,21,large,higher_in_label1(disease)
Effects of PIP2 hydrolysis,0.00010713053610997517,2.6572848382369817e-05,0.7596371882086168,0.033670636956581575,-0.03360514591150569,6.549104507588088e-05,21,21,large,higher_in_label1(disease)
NS1 Mediated Effects on Host Pathways,0.00010713053610997517,2.6572848382369817e-05,0.7596371882086168,0.0078628033763922,-0.0002187565408827,0.0076440468355095,21,21,large,higher_in_label1(disease)
G alpha (12/13) signalling events,0.00011721839863969259,2.9687166235117965e-05,0.7551020408163265,0.05884614610803621,-0.0016914493994319,0.057154696708604305,21,21,large,higher_in_label1(disease)
RAS processing,0.00011721839863969259,2.9687166235117965e-05,0.7551020408163265,0.01731369545381695,-0.00147568053973645,0.0158380149140805,21,21,large,higher_in_label1(disease)
Maturation of spike protein,0.00012954159913079204,3.314641439900162e-05,-0.7505668934240363,-0.0027091641612927,0.0024388449765238,-0.0002703191847689,21,21,large,higher_in_label0(control)
Signaling by VEGF,0.0001430886664244318,3.6986365472633807e-05,-0.746031746031746,-0.1028092195501868,0.1025335480743971,-0.0002756714757897,21,21,large,higher_in_label0(control)
Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC),0.00015797302569445476,4.124622080795164e-05,-0.7414965986394557,-0.0468913811175485,0.0471468162260964,0.0002554351085479,21,21,large,higher_in_label0(control)
RAC2 GTPase cycle,0.00016767706511817434,4.596890819166659e-05,0.7369614512471656,0.019065448248126653,-0.0026456562867397003,0.016419791961386952,21,21,large,higher_in_label1(disease)
MTOR signalling,0.00016767706511817434,4.596890819166659e-05,-0.7369614512471656,-0.06221816333460025,0.06170123019284615,-0.0005169331417541,21,21,large,higher_in_label0(control)
PKA-mediated phosphorylation of CREB,0.00016767706511817434,4.596890819166659e-05,0.7369614512471656,0.0121931649073461,-0.0002683056642084,0.0119248592431377,21,21,large,higher_in_label1(disease)
Frs2-mediated activation,0.00016767706511817434,4.596890819166659e-05,-0.7369614512471656,-0.0285833166291107,0.0283223448542454,-0.0002609717748653,21,21,large,higher_in_label0(control)
Signalling to RAS,0.00016767706511817434,4.596890819166659e-05,0.7369614512471656,0.00287918008505185,-0.0012767919285259,0.00160238815652595,21,21,large,higher_in_label1(disease)
Activated point mutants of FGFR2,0.00018500129262856048,5.120140213740838e-05,-0.7324263038548753,-0.027071171654702648,0.0350230410240091,0.00795186936930645,21,21,large,higher_in_label0(control)
Signaling by ERBB2,0.00020401038425256932,5.699506818544365e-05,-0.727891156462585,-0.04223668790289632,0.04214196705264755,-9.472085024877582e-05,21,21,large,higher_in_label0(control)
The role of Nef in HIV-1 replication and disease pathogenesis,0.0002248565787943047,6.340603266262378e-05,-0.7233560090702948,-0.04029877867985496,0.0402364566498346,-6.232203002036108e-05,21,21,large,higher_in_label0(control)
RHO GTPases Activate WASPs and WAVEs,0.00024106970459041244,7.049557941025116e-05,0.7188208616780045,0.0402614930986978,-0.00261081602909445,0.03765067706960335,21,21,large,higher_in_label1(disease)
Hedgehog 'on' state,0.00024106970459041244,7.049557941025116e-05,0.7188208616780045,0.01057065201252265,-0.0010090169668703,0.009561635045652349,21,21,large,higher_in_label1(disease)
Aberrant regulation of mitotic cell cycle due to RB1 defects,0.00024106970459041244,7.049557941025116e-05,0.7188208616780045,0.0156068845935886,-0.0013928746382519,0.0142140099553367,21,21,large,higher_in_label1(disease)
Interactions of Rev with host cellular proteins,0.00024106970459041244,7.049557941025116e-05,-0.7188208616780045,-0.01948480756529551,0.0194380569024166,-4.675066287891352e-05,21,21,large,higher_in_label0(control)
G-protein beta:gamma signalling,0.0002608748716599408,7.833057504149659e-05,0.7142857142857142,0.04657673176855016,-0.0465100338746913,6.669789385885785e-05,21,21,large,higher_in_label1(disease)
Nuclear import of Rev protein,0.0002608748716599408,7.833057504149659e-05,0.7142857142857142,0.0391871780019855,-0.0389256984557758,0.0002614795462097,21,21,large,higher_in_label1(disease)
Downstream signaling of activated FGFR3,0.0002608748716599408,7.833057504149659e-05,0.7142857142857142,0.03116828176516439,-0.0312465208644028,-7.82390992384087e-05,21,21,large,higher_in_label1(disease)
Defective GALNT12 causes CRCS1,0.0002847422480610377,8.698392434240578e-05,-0.7097505668934241,-0.017205264359314354,0.017002818591879153,-0.0002024457674352,21,21,large,higher_in_label0(control)
Signaling by PTK6,0.0002847422480610377,8.698392434240578e-05,-0.7097505668934241,-0.00657461938178885,0.00644048463578065,-0.0001341347460082,21,21,large,higher_in_label0(control)
Disassembly of the destruction complex and recruitment of AXIN to the membrane,0.0003133298899595763,9.653505748101829e-05,0.7052154195011338,0.00430268767315025,-0.0006297773802073,0.00367291029294295,21,21,large,higher_in_label1(disease)
SARS-CoV-2 modulates autophagy,0.00034460489606998545,0.00010707045073714953,0.7006802721088434,0.014852327655966174,-0.0148528868230831,-5.591671169272306e-07,21,21,large,higher_in_label1(disease)
SARS-CoV-1 modulates host translation machinery,0.00046075401140001804,0.00014556458323603704,0.6870748299319729,0.007919044613708801,-0.001166093714559,0.0067529508991498,21,21,large,higher_in_label1(disease)
RHO GTPases activate PAKs,0.00046075401140001804,0.00014556458323603704,-0.6870748299319728,-0.0067377277379712264,0.0066563697703983,-8.135796757292587e-05,21,21,large,higher_in_label0(control)
Pre-NOTCH Expression and Processing,0.0005591311968764895,0.00017810445435752407,0.6780045351473922,0.04072242872495685,-0.0405629744841378,0.00015945424081904999,21,21,large,higher_in_label1(disease)
Ca2+ pathway,0.0006079534336341421,0.00019683087668572746,-0.6734693877551021,-0.0065997915411776,0.0004790343381016,-0.006120757203076,21,21,large,higher_in_label0(control)
Signaling by FGFR3 in disease,0.0006079534336341421,0.00019683087668572746,0.6734693877551021,0.004101284917116949,-0.000353210049749,0.0037480748673679497,21,21,large,higher_in_label1(disease)
Tat-mediated HIV elongation arrest and recovery,0.0006608142013068239,0.00021739579468579582,0.6689342403628118,0.05602661514861475,-0.055696918276727,0.00032969687188775,21,21,large,higher_in_label1(disease)
Maturation of nucleoprotein,0.0006608142013068239,0.00021739579468579582,0.6689342403628118,0.02530038495717245,-0.0011063481813042499,0.0241940367758682,21,21,large,higher_in_label1(disease)
"Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)",0.0010595626124802913,0.00035410969816573705,0.6462585034013606,0.00755587883398265,-0.00086322519023045,0.0066926536437522,21,21,large,higher_in_label1(disease)
Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants,0.0010595626124802913,0.00035410969816573705,0.6462585034013606,0.02244907150389935,-0.00177653733980315,0.0206725341640962,21,21,large,higher_in_label1(disease)
Respiratory Syncytial Virus Infection Pathway,0.0011481299821320234,0.0003897046936740549,0.6417233560090703,0.05868994489859175,-0.00197802585384995,0.0567119190447418,21,21,large,higher_in_label1(disease)
Signaling by APC mutants,0.0011481299821320234,0.0003897046936740549,-0.6417233560090703,-0.0240468760900931,0.023841366526722703,-0.00020550956337040001,21,21,large,higher_in_label0(control)
NOTCH3 Intracellular Domain Regulates Transcription,0.0012343010717372654,0.00042862152099492506,-0.63718820861678,-0.09278461963928761,0.092682436255984,-0.0001021833833036,21,21,large,higher_in_label0(control)
Signaling by NOTCH3,0.0012343010717372654,0.00042862152099492506,0.6371882086167799,0.012988790210662399,-0.001063092795658,0.0119256974150044,21,21,large,higher_in_label1(disease)
WNT5A-dependent internalization of FZD4,0.0012343010717372654,0.00042862152099492506,0.6371882086167799,0.0158182787292081,-0.0004111391087975,0.0154071396204106,21,21,large,higher_in_label1(disease)
Retrograde neurotrophin signalling,0.0013466259080939906,0.0004711432681059915,0.6326530612244898,0.00487734659636975,0.00014766968166505,0.0050250162780348,21,21,large,higher_in_label1(disease)
Pre-NOTCH Transcription and Translation,0.0016121250263994376,0.0005682425027778696,-0.6235827664399093,-0.11463620346543223,0.1145915427848764,-4.466068055582798e-05,21,21,large,higher_in_label0(control)
Regulation of PTEN stability and activity,0.0017558831760994696,0.0006234989868133887,-0.6190476190476191,-0.022897458961271207,0.0229029294904275,5.470529156291754e-06,21,21,large,higher_in_label0(control)
RHO GTPases activate PKNs,0.0019114253329404205,0.0006837213331927875,-0.6145124716553287,-0.006698537954970701,0.000547455557981,-0.0061510823969897,21,21,large,higher_in_label0(control)
Diseases of metabolism,0.002079618677753892,0.0007493143016450056,0.6099773242630386,0.03124628491002118,-6.029555761857683e-05,0.0311859893524026,21,21,large,higher_in_label1(disease)
Signaling by NOTCH1,0.0022136095930313723,0.0008207116506800389,-0.6054421768707483,-0.03501668514754646,0.0349693403315533,-4.734481599316244e-05,21,21,large,higher_in_label0(control)
TNF signaling,0.0022136095930313723,0.0008207116506800389,-0.6054421768707483,-0.0266351251848855,0.0262769866505814,-0.0003581385343041,21,21,large,higher_in_label0(control)
Activation of RAC1,0.0022136095930313723,0.0008207116506800389,-0.6054421768707483,-0.011452267690552296,0.0115330770116455,8.080932109320372e-05,21,21,large,higher_in_label0(control)
Deactivation of the beta-catenin transactivating complex,0.0022136095930313723,0.0008207116506800389,0.6054421768707483,0.0089992225039312,-0.0008607180982852,0.008138504405646,21,21,large,higher_in_label1(disease)
VEGFR2 mediated vascular permeability,0.002356703548846273,0.0008983778541293888,-0.600907029478458,-0.005008513606509651,0.0048811784282272504,-0.0001273351782824,21,21,large,higher_in_label0(control)
NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux,0.002356703548846273,0.0008983778541293888,0.600907029478458,0.023153067844459547,-0.0013929610034349,0.021760106841024647,21,21,large,higher_in_label1(disease)
Nucleotide-like (purinergic) receptors,0.002356703548846273,0.0008983778541293888,-0.600907029478458,-0.022430840024563792,0.0223545294383282,-7.631058623559171e-05,21,21,large,higher_in_label0(control)
Diseases associated with the TLR signaling cascade,0.002356703548846273,0.0008983778541293888,0.600907029478458,0.010232425646684373,-0.0102294415326065,2.9841140778724224e-06,21,21,large,higher_in_label1(disease)
Listeria monocytogenes entry into host cells,0.002560654335227411,0.000982809888455429,-0.5963718820861679,-0.009213788989024994,0.0092677557322191,5.396674319410587e-05,21,21,large,higher_in_label0(control)
Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function,0.0027620702813267463,0.0010745390911688908,0.5918367346938775,0.001134097410339,-0.0001928326625645,0.0009412647477745,21,21,large,higher_in_label1(disease)
Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R),0.0027620702813267463,0.0010745390911688908,0.5918367346938775,0.02740855318099,-0.0011130503400987,0.0262955028408913,21,21,large,higher_in_label1(disease)
Export of Viral Ribonucleoproteins from Nucleus,0.002978099163174242,0.0011741330904420642,-0.5873015873015873,-0.00019531681341398733,0.00016643035299199256,-2.888646042199476e-05,21,21,large,higher_in_label0(control)
Formation of HIV elongation complex in the absence of HIV Tat,0.002978099163174242,0.0011741330904420642,0.5873015873015872,0.007503587646793284,-0.007526926531595399,-2.333888480211544e-05,21,21,large,higher_in_label1(disease)
Degradation of AXIN,0.003188842594772888,0.0012821978057311351,0.5827664399092971,0.0008183337030580499,-0.0010641758989029,-0.00024584219584485,21,21,large,higher_in_label1(disease)
RHO GTPases activate CIT,0.003188842594772888,0.0012821978057311351,0.5827664399092971,0.0022824521960486503,-0.0010004849527158,0.0012819672433328501,21,21,large,higher_in_label1(disease)
p130Cas linkage to MAPK signaling for integrins,0.003188842594772888,0.0012821978057311351,-0.5827664399092971,-0.0006994316223263059,-1.732802009594068e-06,-0.0007011644243359,21,21,large,higher_in_label0(control)
Signaling by NOTCH4,0.0034356561265893684,0.001399379518924129,-0.5782312925170068,-0.0140377407448402,0.01397855168571355,-5.9189059126648725e-05,21,21,large,higher_in_label0(control)
Signaling by Non-Receptor Tyrosine Kinases,0.0034356561265893684,0.001399379518924129,0.5782312925170068,0.0007706199325601498,-0.0010061863719173498,-0.0002355664393572,21,21,large,higher_in_label1(disease)
IRS-related events triggered by IGF1R,0.004059053009790278,0.0016638937925249964,-0.5691609977324263,-0.004672003825819845,0.0046429011472017,-2.9102678618145077e-05,21,21,large,higher_in_label0(control)
HIV elongation arrest and recovery,0.004285676231312642,0.0018127403380486893,0.564625850340136,0.002977202557368477,9.650220000017292e-05,0.0030737047573686496,21,21,large,higher_in_label1(disease)
MAP2K and MAPK activation,0.004285676231312642,0.0018127403380486893,-0.564625850340136,-0.03736643117501938,0.0373244224232169,-4.20087518024796e-05,21,21,large,higher_in_label0(control)
SARS-CoV-1 targets host intracellular signalling and regulatory pathways,0.004285676231312642,0.0018127403380486893,0.564625850340136,0.0112861907231727,-0.0010896161784065,0.0101965745447662,21,21,large,higher_in_label1(disease)
Signaling by ERBB2 ECD mutants,0.004285676231312642,0.0018127403380486893,-0.564625850340136,-0.004592868088954951,0.004547284666878501,-4.5583422076449895e-05,21,21,large,higher_in_label0(control)
RAF activation,0.004285676231312642,0.0018127403380486893,0.564625850340136,0.0012558861179435502,-7.48863200081002e-05,0.00118099979793545,21,21,large,higher_in_label1(disease)
Serotonin receptors,0.004637675263541224,0.0019737364698621924,-0.5600907029478458,-0.005750281253347826,0.0057810064054567,3.072515210887504e-05,21,21,large,higher_in_label0(control)
InlB-mediated entry of Listeria monocytogenes into host cell,0.004985415230097402,0.0021477637414257737,-0.5555555555555556,-0.0858570696146686,0.0854846374242314,-0.0003724321904372,21,21,large,higher_in_label0(control)
Signaling by CTNNB1 phospho-site mutants,0.004985415230097402,0.0021477637414257737,-0.5555555555555556,-0.0032538441256015965,0.00317042941679925,-8.341470880234686e-05,21,21,large,higher_in_label0(control)
Nuclear Events (kinase and transcription factor activation),0.00538912818100074,0.002335757906125647,-0.5510204081632653,-0.047787569340416676,0.04776747747492295,-2.009186549372288e-05,21,21,large,higher_in_label0(control)
Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models,0.005787657625043518,0.0025387114386613866,0.5464852607709751,0.0137574853133341,-0.0014376372392383,0.0123198480740958,21,21,large,higher_in_label1(disease)
HIV Transcription Initiation,0.005787657625043518,0.0025387114386613866,0.5464852607709751,0.0039124579910874,-0.0006214731967266,0.0032909847943608,21,21,large,higher_in_label1(disease)
RHOB GTPase cycle,0.006212882058607949,0.002757676109564886,0.5419501133786848,0.0290182094929471,-0.00134831759808685,0.02766989189486025,21,21,large,higher_in_label1(disease)
Nuclear events stimulated by ALK signaling in cancer,0.006212882058607949,0.002757676109564886,-0.5419501133786848,-0.059022187579712754,0.0590674325736255,4.524499391274413e-05,21,21,large,higher_in_label0(control)
RHOBTB1 GTPase cycle,0.00662781634743769,0.0029937656086337344,0.5374149659863945,0.0072570685041198,-0.0009154575430513,0.0063416109610685,21,21,large,higher_in_label1(disease)
Downregulation of TGF-beta receptor signaling,0.00662781634743769,0.0029937656086337344,0.5374149659863945,0.011592947393892196,-0.0115919730841692,9.743097229970629e-07,21,21,large,higher_in_label1(disease)
Pre-NOTCH Processing in Golgi,0.00662781634743769,0.0029937656086337344,0.5374149659863945,0.0034280760216744,-0.0011593972354370999,0.0022686787862373,21,21,large,higher_in_label1(disease)
P2Y receptors,0.007149681582761383,0.003248158212533892,0.5328798185941044,0.012611399495369581,-6.35268217127299e-05,0.01254787267365685,21,21,large,higher_in_label1(disease)
NEP/NS2 Interacts with the Cellular Export Machinery,0.008353569333006709,0.0038169050477184704,0.5238095238095237,0.00076532736133505,-0.0003407543117261,0.00042457304960895,21,21,large,higher_in_label1(disease)
Formation of HIV-1 elongation complex containing HIV-1 Tat,0.009682625564591924,0.004474738185203056,-0.5147392290249433,-0.023787168020809,0.0236731911342274,-0.0001139768865816,21,21,large,higher_in_label0(control)
Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer,0.009682625564591924,0.004474738185203056,0.5147392290249433,0.012865808881690801,-0.0127747627710814,9.104611060940022e-05,21,21,large,higher_in_label1(disease)
CaMK IV-mediated phosphorylation of CREB,0.010357629733096039,0.004840772120689793,-0.5102040816326531,-0.0010759100728370999,0.0009739064208508499,-0.00010200365198625,21,21,large,higher_in_label0(control)
Defects in vitamin and cofactor metabolism,0.010357629733096039,0.004840772120689793,-0.5102040816326531,-0.006172097371560598,0.006078548964267,-9.354840729359746e-05,21,21,large,higher_in_label0(control)
Signaling by FGFR4,0.011013751371433112,0.005233688641255421,0.5056689342403629,0.0056386684234321005,-0.0008434168316962,0.0047952515917359,21,21,large,higher_in_label1(disease)
FCGR3A-mediated IL10 synthesis,0.011013751371433112,0.005233688641255421,-0.5056689342403629,-0.0035704433031665136,-7.772148929778599e-05,-0.0036481647924642997,21,21,large,higher_in_label0(control)
PI-3K cascade:FGFR2,0.011013751371433112,0.005233688641255421,-0.5056689342403629,-0.00053957023711035,0.0003112368442447,-0.00022833339286565,21,21,large,higher_in_label0(control)
Diseases of programmed cell death,0.011771411907652128,0.005655195276783268,0.5011337868480725,0.0079391745798425,-0.000873908530541,0.0070652660493015,21,21,large,higher_in_label1(disease)
Diseases of DNA Double-Strand Break Repair,0.011771411907652128,0.005655195276783268,0.5011337868480725,0.0004285501175279373,-0.0004330910226561,-4.540905128162726e-06,21,21,large,higher_in_label1(disease)
Purinergic signaling in leishmaniasis infection,0.014718895087851623,0.007109649063322586,0.48752834467120176,0.0123298472647458,-0.0006190432344122,0.0117108040303336,21,21,large,higher_in_label1(disease)
Potential therapeutics for SARS,0.015697608828565565,0.007664367757028096,0.48299319727891166,0.0259255691761828,-0.0259158403691234,9.728807059399456e-06,21,21,large,higher_in_label1(disease)
p75NTR signals via NF-kB,0.015697608828565565,0.007664367757028096,0.48299319727891166,0.0025094620418845,-0.0007372799721703,0.0017721820697141999,21,21,large,higher_in_label1(disease)
Degradation of GLI2 by the proteasome,0.01682260294562426,0.008257570114301203,0.47845804988662133,0.04150374973273155,-0.041538280239782094,-3.4530507050544546e-05,21,21,large,higher_in_label1(disease)
RNA Polymerase II HIV Promoter Escape,0.0180182748475737,0.008891524663685195,0.473922902494331,0.011726557718064173,3.285860859712799e-05,0.0117594163266613,21,21,medium,higher_in_label1(disease)
Energy dependent regulation of mTOR by LKB1-AMPK,0.020745052661695254,0.01029127938830835,0.46485260770975056,0.0089263799628126,-0.0011153053192988998,0.0078110746435137,21,21,medium,higher_in_label1(disease)
Negative regulation of MET activity,0.021952326677129194,0.011062138508318366,-0.46031746031746035,-0.0005764879294257968,0.00057397952344405,-2.5084059817468742e-06,21,21,medium,higher_in_label0(control)
Adenylate cyclase inhibitory pathway,0.021952326677129194,0.011062138508318366,-0.46031746031746035,-0.0053457034691760325,0.0053720191618998,2.63156927237672e-05,21,21,medium,higher_in_label0(control)
AXIN missense mutants destabilize the destruction complex,0.021952326677129194,0.011062138508318366,-0.46031746031746035,-0.004163052310068997,-4.8784351723803e-05,-0.0042118366617928,21,21,medium,higher_in_label0(control)
Signalling to ERKs,0.023461458764964648,0.011883872063715774,-0.45578231292517,-0.0032504366195819996,0.0002420182137637,-0.0030084184058182997,21,21,medium,higher_in_label0(control)
SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription,0.024932681535785865,0.012759283501342113,-0.4512471655328798,-0.0191338817076924,0.019468747685719,0.0003348659780266,21,21,medium,higher_in_label0(control)
Signaling by moderate kinase activity BRAF mutants,0.024932681535785865,0.012759283501342113,0.4512471655328798,0.01044688376858902,-7.269936768802043e-05,0.010374184400901,21,21,medium,higher_in_label1(disease)
Signaling by Hippo,0.026618090302609997,0.013691289267922114,-0.4467120181405896,-0.0002696118703708334,-7.38268123226663e-06,-0.0002769945516031,21,21,medium,higher_in_label0(control)
Signaling by ALK,0.02811779264257672,0.014682920439987845,0.44217687074829937,0.003191751023832808,-0.0032134127783216,-2.1661754488791872e-05,21,21,medium,higher_in_label1(disease)
CTNNB1 S45 mutants aren't phosphorylated,0.02811779264257672,0.014682920439987845,-0.44217687074829937,-0.007441308543632338,0.0074328361974316,-8.472346200737812e-06,21,21,medium,higher_in_label0(control)
Regulation of FZD by ubiquitination,0.02811779264257672,0.014682920439987845,-0.44217687074829937,-0.00134911420169961,0.00134876240375155,-3.51797948059792e-07,21,21,medium,higher_in_label0(control)
PLC beta mediated events,0.029838589867486057,0.015737324159875152,0.43764172335600904,0.08991810153633281,-0.0898412993725082,7.680216382460183e-05,21,21,medium,higher_in_label1(disease)
Signaling by WNT in cancer,0.029838589867486057,0.015737324159875152,-0.43764172335600904,-0.004402042042523499,0.0043541485898952,-4.78934526282988e-05,21,21,medium,higher_in_label0(control)
SARS-CoV-2 activates/modulates innate and adaptive immune responses,0.034050445692229876,0.018047625262461266,0.4285714285714286,0.00226581345796285,-0.0024016697983995,-0.00013585634043665002,21,21,medium,higher_in_label1(disease)
Signaling by FGFR1 in disease,0.03607749233209605,0.01931040712292347,-0.4240362811791383,-0.0009248820770090859,1.661803007985824e-06,-0.0009232202740011,21,21,medium,higher_in_label0(control)
Signaling by NTRK3 (TRKC),0.03607749233209605,0.01931040712292347,0.4240362811791383,0.00032368072351149477,-0.00032410658858955,-4.2586507805522594e-07,21,21,medium,higher_in_label1(disease)
Constitutive Signaling by EGFRvIII,0.03839246237887094,0.020649731723361393,0.41950113378684817,0.0008773059999025999,-0.0009902525955425,-0.0001129465956399,21,21,medium,higher_in_label1(disease)
GLI3 is processed to GLI3R by the proteasome,0.0408336098943855,0.02206934007346684,-0.41496598639455784,-7.415688686812524e-05,9.361392234599839e-06,-6.47954946335254e-05,21,21,medium,higher_in_label0(control)
TGF-beta receptor signaling activates SMADs,0.04299283118400897,0.023573092816297346,0.4104308390022675,0.0013270501580156637,-0.0013678246940281502,-4.0774536012486485e-05,21,21,medium,higher_in_label1(disease)
RHO GTPases activate IQGAPs,0.04299283118400897,0.023573092816297346,0.4104308390022675,0.00040050540043982193,-0.00048137059573215,-8.086519529232805e-05,21,21,medium,higher_in_label1(disease)
Signaling by PDGF,0.04299283118400897,0.023573092816297346,0.4104308390022675,0.00843376456753725,-0.0005058005999260501,0.0079279639676112,21,21,medium,higher_in_label1(disease)
NRIF signals cell death from the nucleus,0.04567859450004124,0.025164969815949612,0.4058956916099774,0.0014115367041650502,-0.0015685455603828501,-0.0001570088562178,21,21,medium,higher_in_label1(disease)
Diseases associated with O-glycosylation of proteins,0.048277904150967034,0.026849069410328923,0.4013605442176871,0.000358731562989163,-0.0004219884386573,-6.325687566813698e-05,21,21,medium,higher_in_label1(disease)
HCMV Early Events,0.048277904150967034,0.026849069410328923,-0.4013605442176871,-0.0013246488324830234,9.498878059823413e-06,-0.0013151499544232,21,21,medium,higher_in_label0(control)
